Search

Your search keyword '"van der Kruijssen, Dave E. W."' showing total 14 results
Start Over Author "van der Kruijssen, Dave E. W."
14 results on '"van der Kruijssen, Dave E. W."'

3. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018

Author

Researchgr. Beeldg. Moleculaire Interv., Cancer, MS Medische Oncologie, Onderzoek Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Speerpunt Cancer, de Maar, Josanne S, Luyendijk, Marianne, Suelmann, Britt B M, van der Kruijssen, Dave E W, Elias, Sjoerd G, Siesling, Sabine, van der Wall, Elsken, Researchgr. Beeldg. Moleculaire Interv., Cancer, MS Medische Oncologie, Onderzoek Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Speerpunt Cancer, de Maar, Josanne S, Luyendijk, Marianne, Suelmann, Britt B M, van der Kruijssen, Dave E W, Elias, Sjoerd G, Siesling, Sabine, and van der Wall, Elsken

Published
2023

4. Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a population-based study and meta-analysis

Author

Cancer, Onderzoek Medische Oncologie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, MS Medische Oncologie, van der Kruijssen, Dave E W, van der Kuil, Auke J S, Vink, Geraldine R, Punt, Cornelis J A, de Wilt, Johannes H W, Elias, Sjoerd G, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, MS Medische Oncologie, van der Kruijssen, Dave E W, van der Kuil, Auke J S, Vink, Geraldine R, Punt, Cornelis J A, de Wilt, Johannes H W, Elias, Sjoerd G, and Koopman, Miriam

Published
2023

5. Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment

Author

van der Kruijssen, Dave E W, Elias, Sjoerd G, Vink, Geraldine R, van Rooijen, Karlijn L, 't Lam-Boer, Jorine, Mol, Linda, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam, De Hingh, Ignace, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Epidemiologie, Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
Male, medicine.medical_specialty, Palliative care, Bevacizumab, Colorectal cancer, SURGERY, IMPACT, medicine.medical_treatment, Denmark, MULTICENTER, Netherlands/epidemiology, Gastroenterology, law.invention, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Randomized controlled trial, INFLAMMATION, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, NO RESECTION, Medicine, Humans, LOCATION, Netherlands, Aged, Chemotherapy, biology, business.industry, Mortality rate, Colorectal Neoplasms/drug therapy, Middle Aged, medicine.disease, Primary tumor, Editorial from the ACHBPT, Denmark/epidemiology, PROGNOSTIC VALUE, Alanine transaminase, Biomarkers, Tumor/blood, biology.protein, SURVIVAL, Tumor/blood, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, business, Colorectal Neoplasms, Biomarkers, medicine.drug
Abstract

Importance: The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent symptoms of their primary tumor is unclear. Studying subgroups with low postoperative mortality may identify patients who potentially benefit from PTR.Objective: To determine the difference in 60-day mortality between patients randomized to systemic treatment only vs PTR followed by systemic treatment, and to explore risk factors associated with 60-day mortality.Design, Setting, and Participants: CAIRO4 is a randomized phase 3 trial initiated in 2012 in which patients with mCRC were randomized to systemic treatment only or PTR followed by systemic treatment with palliative intent. This multicenter study was conducted by the Danish and Dutch Colorectal Cancer Group in general and academic hospitals in Denmark and the Netherlands. Patients included between August 2012 and December 2019 with histologically proven colorectal cancer, unresectable metastases, and a primary tumor with few or absent symptoms were eligible.Interventions: Systemic treatment, consisting of fluoropyrimidine-based chemotherapy with bevacizumab vs PTR followed by fluoropyrimidine-based chemotherapy with bevacizumab.Main Outcomes and Measures: The aim of the current analysis was to compare 60-day mortality rates in both treatment arms. A secondary aim was the identification of risk factors for 60-day mortality in the treatment arms. These aims were not predefined in the study protocol.Results: A total of 196 patients were included in the intention-to-treat analysis (112 [57%] men; median [IQR] age, 65 [59-70] years). Sixty-day mortality was 3% (95% CI, 1%-9%) in the systemic treatment arm and 11% (95% CI, 6%-19%) in the PTR arm (P = .03). In a per-protocol analysis, 60-day mortality was 2% (95% CI, 1%-7%) vs 10% (95% CI, 5%-18%; P = .048). Patients with elevated serum levels of lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, and/or neutrophils who were randomized to PTR had a significantly higher 60-day mortality than patients without these characteristics.Conclusions and Relevance: Patients with mCRC who were randomized to PTR followed by systemic treatment had a higher 60-day mortality than patients randomized to systemic treatment. Especially patients randomized to the PTR arm with elevated serum levels of lactate dehydrogenase, neutrophils, aspartate aminotransferase, and/or alanine aminotransferase were at high risk of postoperative mortality. Final study results on overall survival have to be awaited.Trial Registration: ClinicalTrials.gov Identifier: NCT01606098.

Published
2021
Full Text
View/download PDF

7. Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis.

Author

van der Kruijssen, Dave E. W., van der Kuil, Auke J. S., Vink, Geraldine R., Punt, Cornelis J. A., de Wilt, Johannes H. W., Elias, Sjoerd G., and Koopman, Miriam

Subjects
PROGNOSIS, COLORECTAL cancer, METASTASIS, OVERALL survival, DATABASES
Abstract

We studied the prognostic value of primary tumor sidedness in metastatic colorectal cancer over time and across treatment lines. Population data on synchronous metastatic colorectal cancer patients were extracted from the Netherlands Cancer Registry and SEER database. Pubmed, EMBASE and Cochrane library were searched for prospective studies on metastatic colorectal cancer to conduct a meta‐analysis. Inclusion criteria consisted of metastatic disease, systemic treatment with palliative intent and specification of primary tumor location. Data were pooled using a random‐effects model. For the population‐based data, multivariable Cox models were constructed. The Grambsch‐Therneau test was conducted to evaluate the potential time‐varying nature of sidedness. Meta‐regression incorporating treatment‐line as variable was conducted to test the pre‐specified hypothesis that the prognostic value of sidedness varies over time. Analysis of 12 885 and 16 160 synchronous metastatic colorectal cancer patients registered in the Netherlands Cancer Registry and SEER database, respectively, indicated a time‐varying prognostic value of sidedness (P <.01). Thirty‐one studies were selected for the meta‐analysis (9558 patients for overall survival analysis). Pooled univariable hazard ratioleft‐sided/right‐sided for overall survival was 0.71 (95% CI: 0.65‐0.76) in 1st‐line, 0.76 (0.54‐1.06) in 2nd‐line and 1.01 (0.86‐1.19) in 3rd‐line studies. Hazard ratios were significantly influenced by treatment line (P =.035). The prognostic value of sidedness of the primary tumor in metastatic colorectal cancer patients treated with palliative systemic therapy decreases over time since diagnosis, suggesting that sidedness may not be a useful stratification factor in late‐line trials. This decrease in prognostic value should be taken into account when providing prognostic information to patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer: A Population-Based Study

Author

Cancer, Onderzoek Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, Brouwer, Nelleke PM, van der Kuil, Auke J S, Verhoeven, Rob H A, Elias, Sjoerd G, Vink, Geraldine R, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, Brouwer, Nelleke PM, van der Kuil, Auke J S, Verhoeven, Rob H A, Elias, Sjoerd G, Vink, Geraldine R, Punt, Cornelis J A, de Wilt, Johannes H W, and Koopman, Miriam

Published
2021

10. Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients

Author

Cancer, Onderzoek Medische Oncologie, Arts-assistenten Radiotherapie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes HW, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, Arts-assistenten Radiotherapie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes HW, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, and Koopman, Miriam

Published
2021

11. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival

Author

Onderzoek Medische Oncologie, Cancer, MS Medische Oncologie, Brouwer, Nelleke P M, van der Kruijssen, Dave E W, Hugen, Niek, de Hingh, Ignace H J T, Nagtegaal, Iris D, Verhoeven, Rob H A, Koopman, Miriam, de Wilt, Johannes H W, Onderzoek Medische Oncologie, Cancer, MS Medische Oncologie, Brouwer, Nelleke P M, van der Kruijssen, Dave E W, Hugen, Niek, de Hingh, Ignace H J T, Nagtegaal, Iris D, Verhoeven, Rob H A, Koopman, Miriam, and de Wilt, Johannes H W

Published
2020

14. Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients.

Author

van der Kruijssen DEW, van Rooijen KL, Kurk SA, de Wilt JHW, Punt CJA, Vink GR, Elias SG, and Koopman M

Subjects
Humans, Retrospective Studies, Survival Analysis, Treatment Outcome, Colonic Neoplasms pathology, Colonic Neoplasms surgery
Abstract

Introduction: Uncertainty exists about a possible survival benefit of primary tumor resection (PTR) in synchronous metastatic colon cancer (mCC). Since sidedness of the primary tumor is regarded as an important prognostic factor, our objective was to study the interaction between PTR and sidedness in synchronous mCC., Methods: In this retrospective study, we used data from 2 first-line phase 3 randomized controlled trials (RCTs). A mixed Cox regression model was used to study the multiplicative interaction between PTR and sidedness. We adjusted for age, treatment arm, WHO performance status, number of affected organs by metastases, serum lactate dehydrogenase, and year of enrollment., Results: We found that PTR is associated with better survival in both right-sided (hazard ratio [HR] 0.59 [95% confidence interval 0.42-0.8 2]) and left-sided mCC (HR 0.70 [95% confidence interval 0.52-0.93]). The interaction between PTR and sidedness was not significant (p = 0.45)., Conclusion: Our data suggest that the prognostic value of PTR is independent of sidedness. Validation of these results will be performed in ongoing RCTs., (© 2021 S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results